Panel Discussion

Monday, March 9, 2026

4:30 PM - 5:00 PM EST

Location: Monroe

Moderator(s)

NG

Nicole Gillette

Assistant Director
FDA
Silver Spring, Maryland, United States

Disclosure information not submitted.
Daniel Burkhoff, MD, PhD

Director: Heart Failure, Hemodynamics and MCS Research
Cardiovascular Research Foundation
New York, New York, United States

Disclosure(s): Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Panel Discussant(s)

DB

David Berg

Disclosure information not submitted.
AC

Aaron Chalekian

Disclosure information not submitted.
Ian C. Gilchrist, Sr., MD, MSCAI

Professor of Interventional Cardiology
Dartmouth Hitchcock Medical Center
Moultonborough, New Hampshire, United States

Disclosure(s): No financial relationships to disclose
Jacob Eifer Møller, MD

Consultant
Rigshospitalet Copenhagen Denmark

Disclosure(s): Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Magenta,: Consulting Fees (e.g., advisory boards) (Ongoing)
CR

Christine Rutan

Disclosure information not submitted.
Alexander G. Truesdell, MD

Interventional Cardiology
Virginia Heart / Inova Schar Heart and Vascular
McLean, Virginia, United States

Disclosure(s): Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chiesi: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Zoll: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Ron Waksman, MD, MSCAI

Director, Cardiovascular Research and Advanced Education
MedStar Washington Hospital Center, MedStar Heart and Vascular Institute
Washington, District of Columbia, United States

Disclosure information not submitted.

Disclosure(s):

Daniel Burkhoff, MD, PhD: Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Ian C. Gilchrist, MD, MSCAI, Sr.: No financial relationships to disclose

Jacob Eifer Møller, MD: Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Magenta,: Consulting Fees (e.g., advisory boards) (Ongoing)

Alexander G. Truesdell, MD: Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chiesi: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Zoll: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)